RxDoctor Payments Data

Lynn Thompson-Gregory

Nurse Practitioner · State College, PANPI 1477583342

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (40.2%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Amgen accounts for 93.7% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $9,164, more than ten times the $60 reported in 2021. Among nurse practitioner clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,819in general payments, 2019–2025

Across 63 payments — averaging $171.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$10K
  • Radius Health, Inc.$321
  • Kyowa Kirin, Inc.$199
  • AstraZeneca$104
  • Johnson & Johnson$28
  • Almatica Pharma LLC$20
  • plus $14 from 1 others

What the payments were for

  • Consulting fees$4,34540%
  • Speaking & faculty fees$2,00018%
  • Travel & lodging$1,94118%
  • Food & beverage$2,51023%
  • Education$240%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,819 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$1,057,344
Medicare patients
495
Services billed
75,154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TymlosAbaloparatide306$897,012
Teriparatide181$460,609
Evenity (2 Syringes)Romosozumab-Aqqg146$331,315
ForteoTeriparatide76$304,190
ProliaDenosumab118$183,182
Risedronate Sodium40$4,025
Ibandronate Sodium125$3,738
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic36$1,705
Alendronate Sodium42$668
Droplet Pen NeedlePen Needle, Diabetic14$457
Diclofenac Sodium19$320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Radius Health, Inc.Tymlos$321$897,012306 claims
AmgenEvenity (2 Syringes), Prolia$10,134$514,497264 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in State College

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →